



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 8, 2015

Via E-mail

Steven A. Victor  
Chief Executive Officer  
Intellicell Biosciences, Inc.  
460 Park Avenue, 17th Floor  
New York, NY 10022

**Re: Intellicell Biosciences, Inc.  
Preliminary Information Statement on Schedule 14C  
Filed December 23, 2014  
File No. 000-54729**

Dear Dr. Victor:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Jeffrey P. Riedler

Jeffrey P. Riedler  
Assistant Director